Aterixen® (ХС221GI) as an effective and safe remedy for treatment of COVID-19, influenza and other acute respiratory viral infections treatment: Review of clinical studies


DOI: https://dx.doi.org/10.18565/therapy.2024.2.156-163

Kalyuzhin O.V.

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), Moscow
Abstract. Excessive inflammatory response taking place during respiratory tract infections, including COVID-19, influenza and other seasonal acute respiratory viral infections (ARVI), is a critical factor of endogenous damage of the organism and a key target for therapeutic interventions in patients with these diseases. In 2022, innovative drug Aterixen® (ХС221GI), with the ability to block/ prevent virus-induced release of pro-inflammatory cytokines and chemokines, was approved for the treatment of mild forms of COVID-19 in Russia. In 2023, indications for use of the drug were expanded to include influenza and other seasonal ARVI. Current narrative review analyzes the results of recently published two randomized placebo-controlled clinical trials and one observational study of Aterixen® in patients with COVID-19, as well as one randomized placebo-controlled trial in patients with influenza and ARVI. The presented data indicate that Aterixen® blocks universal chains in the pathogenesis of viral respiratory diseases of different etiologies and has a positive effect on their clinically significant outcomes. That allows to formulate convincing recommendations for the use of this medicine in the complex therapy of COVID-19, influenza and other seasonal ARVIs.
Keywords: placebo, imidazole derivatives, XC221GI, Aterixen®, COVID-19, randomized controlled trial, influenza, acute respiratory viral infections, observational study
Read entire article

Literature

1. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственного препарата Атериксен®, таблетки 100 мг. РУ: ЛП-007921. Доступ: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=373efbfc-f5d0-40a2-8474-2a87eb0b753f (дата обращения – 12.03.2024). [State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Aterixen®, tablets 100 mg. Registration certificate: ЛП-007921. URL: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=373efbfc-f5d0-40a2-8474-2a87eb0b753f (date of access – 12.03.2024).


2. Siwach A., Verma P.K. Synthesis and therapeutic potential of imidazole containing compounds. BMC Chem. 2021; 15(1): 12.


https://doi.org/10.1186/s13065-020-00730-1. PMID: 33602331. PMCID: PMC7893931.


3. Стукова М.А., Рыдловская А.В., Проскурина О.В. с соавт. Фармакодинамическая активность нового соединения XC221GI в in vitro и in vivo моделях вирусного воспаления респираторного тракта. Независимые микробиологические исследования. 2022; 9(1): 56–70. [Stukova М.А., Rydlovskaya A.V., Proskurina O.V. et al. In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. Nezavisimyye mikrobiologicheskiye issledovaniya = Microbiology Independent Research Journal. 2022; 9(1): 56–70 (In Russ.)].


https://doi.org/10.18527/2500-2236-2022-9-1-56-70. EDN: BGIJDV.


4. Горелов А.В., Калюжин О.В., Багаева М.И. Новые возможности упреждающей противовоспалительной терапии пациентов со среднетяжелой и тяжелой формой COVID-19. Терапевтический архив. 2022; 94(7): 872–875. [Gorelov A.V., Kalyuzhin O.V., Bagaeva M.I. New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(7): 872–875 (In Russ.)].


https://doi.org/10.26442/00403660.2022.07.201729. EDN: VJHZPJ.


5. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 9 (26.10.2020). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/МР_COVID-19_%28v.9%29.pdf (дата обращения – 12.03.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 9 (10/26/2020). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/МР_COVID-19_%28v.9%29.pdf (date of access – 01.02.2024) (In Russ.)].


6. Myrstad M., Ihle-Hansen H., Tveita A.A. et al. National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from COVID-19 – a prospective cohort study. Scand J Trauma Resusc Emerg Med. 2020; 28(1): 66.


https://doi.org/10.1186/s13049-020-00764-3. PMID: 32660623. PMCID: PMC7356106.


7. Калюжин О.В., Баранова А., Багаева М.И. Стратегия управления вирусиндуцированным воспалением при COVID-19. Результаты многоцентрового адаптивного рандомизированного двойного слепого плацебо-контролируемого исследования у амбулаторных пациентов. Инфекционные болезни. 2023; 21(1): 26–35. [Kalyuzhin O.V., Baranova A., Bagaeva M.I. Management strategy for virus-induced inflammation in COVID-19. Results of a multicenter, adaptive, randomized, double-blind, placebo-controlled study in outpatients. Infektsionnyye bolezni = Infectious Diseases. 2023; 21(1): 26–35 (In Russ.)].


https://doi.org/10.20953/1729-9225-2023-1-26-34. EDN: WUYRNT.


8. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 11 (07.05.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/736/original/BMP-11.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 11 (05/07/2021). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/736/original/BMP-11.pdf (date of access – 01.02.2024) (In Russ.)].


9. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 12 (21.09.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/ВМР_COVID-19_V12.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 12 (09/21/2021). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/ВМР_COVID-19_V12.pdf (date of access – 01.02.2024) (In Russ.)].


10. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 13 (14.10.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 13 (10/14/2021). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (date of access – 01.02.2024) (In Russ.)].


11. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 14 (27.12.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/ВМР_COVID-19_V14_27-12-2021.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 14 (12/27/2021). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/ВМР_COVID-19_V14_27-12-2021.pdf (date of access – 01.02.2024) (In Russ.)].


12. Кулагина И.Ц., Багаева М.И. Опыт применения препарата Атериксен® в клинической практике. Результаты наблюдательной программы «СУПРА». Consilium Medicum. 2023; 25(9): 573–576. [Kulagina I.T., Bagaeva M.I. Experience in using Aterixen® in clinical practice. Results of the “SUPRA” observation program. Consilium Medicum. 2023; 25(9): 573–576 (In Russ.)].


https://doi.org/10.26442/20751753.2023.9.202401. EDN: QKPAQP.


13. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 16 (22.02.2022). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/ВМР_COVID-19_V16.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 16 (02/22/2022). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/ВМР_COVID-19_V16.pdf (date of access – 01.02.2024) (In Russ.)].


14. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 17 (14.12.2022). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/ВМР_COVID-19_V17.pdf (дата обращения – 01.02.2024). [Interim guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 17 (12/14/2022). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/ВМР_COVID-19_V17.pdf (date of access – 01.02.2024) (In Russ.)].


15. Малявин А.Г., Багаева М.И., Калюжин О.В. Применение ХС221GI в лечении гриппа и ОРВИ у взрослых: новый подход – управление вирусиндуцированным воспалением. Результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового клинического исследования. Терапевтический архив. 2023; 95(12): 1165–1171. [Malyavin A.G., Bagaeva M.I., Kalyuzhin O.V. Application of HS221GI in treatment of influenza and arvi in adults: A new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial. Terapevticheskiy arkhiv = Therapeutic Archive. 2023; 95(12): 1165–1171 (In Russ.)].


https://doi.org/10.26442/00403660.2023.12.202554. EDN: JBOADP.


16. Rinott E., Kozer E., Shapira Y. et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020; 26(9): 1259.e5–1259.e7.


https://doi.org/10.1016/j.cmi.2020.06.003. PMID: 32535147. PMCID: PMC7289730.


17. Reese J.T., Coleman B., Chan L. et al. NSAID use and clinical outcomes in COVID-19 patients: A 38-center retrospective cohort study. Virol J. 2022; 19(1): 84.


https://doi.org/10.1186/s12985-022-01813-2. PMID: 35570298. PMCID: PMC9107579.


18. Graham N.M., Burrell C.J., Douglas R.M. et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis. 1990; 162(6): 1277–82.


https://doi.org/10.1093/infdis/162.6.1277. PMID: 2172402.


19. Plaisance K.I., Kudaravalli S., Wasserman S.S. et al. Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections. Pharmacotherapy. 2000; 20(12): 1417–22.


https://doi.org/10.1592/phco.20.19.1417.34865. PMID: 11130213.


20. Eyers S., Weatherall M., Shirtcliffe P. et al. The effect on mortality of antipyretics in the treatment of influenza infection: Systematic review and meta-analysis. J R Soc Med. 2010; 103(10): 403–11.


https://doi.org/10.1258/jrsm.2010.090441. PMID: 20929891. PMCID: PMC2951171.


21. Ni Y.N., Chen G., Sun J. et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: A systematic review and meta-analysis. Crit Care. 2019; 23(1): 99.


https://doi.org/10.1186/s13054-019-2395-8. PMID: 30917856. PMCID: PMC6437920.


22. Lansbury L.E., Rodrigo C., Leonardi-Bee J. et al. Corticosteroids as adjunctive therapy in the treatment of influenza: An updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020; 48(2): e98–e106.


https://doi.org/10.1097/CCM.0000000000004093. PMID: 31939808.


23. Singanayagam A., Glanville N., Girkin J.L. et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018; 9(1): 2229.


https://doi.org/10.1038/s41467-018-04574-1. PMID: 29884817. PMCID: PMC5993715.


About the Autors

Oleg V. Kalyuzhin, MD, Dr. Sci. (Medicine), professor, professor of the Department of clinical immunology and allergy of the Institute of clinical medicine named after N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Address: 119048, Moscow, 8-2 Trubetskaya St.
E-mail: kalyuzhin@list.ru
ORCID: https://orcid.org/0000-0003-3628-2436


Similar Articles

Back to Content

Бионика Медиа